TG Therapeutics, Inc. (TGTX): Shareholders' Equity
$648.02M
As of 2025-12-31
$604.08M
As of 2026-06-30
+122.8%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $648.02M | +191.4% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $222.36M | +38.5% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $160.50M | +174.0% | 2026-02-27, Balance as of period end |
| 2022-12-31 | $58.59M | -75.3% | 2025-03-03, Balance as of period end |
| 2021-12-31 | $237.15M | n/a | 2024-02-29, Balance as of period end |
| No annual figure between 2012-12-31 and 2021-12-31. | |||
| 2012-12-31 | $15.55M | +61.6% | 2013-03-21, Balance as of period end |
| 2011-12-31 | $9.62M | n/a | 2013-03-21, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $648.02M | +191.4% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.27B | -7.1% |
| Insmed Inc (INSM) | 2025-12-31 | $738.98M | +158.9% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $88.30M | +54.9% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$80.00M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $300.13M | +14.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $1.25B | +62.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.06B | +2.5% |
Compare TGTX, OPK, INSM, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗